Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)

This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Gemin X ) Identifier:
First received: May 23, 2008
Last updated: August 16, 2013
Last verified: August 2013
This protocol will evaluate the efficacy of obatoclax in older patients with previously untreated AML.

Condition Intervention Phase
Drug: Obatoclax
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, 2-Stage, Phase II Study of Single-Agent Obatoclax Mesylate Administered For Three Consecutive Days Every 2 Weeks to Older Patients With Previously Untreated Acute Myeloid Leukemia (AML)

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Determine the rate of morphologic CR after treatment in the obatoclax single-agent therapy in older patients with previously untreated AML. [ Time Frame: 4 weeks ]

Enrollment: 18
Study Start Date: April 2008
Study Completion Date: December 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Experimental
In the Pilot Schedule portion of the study 3 hour vs 24 hour infusion schedules of obatoclax.
Drug: Obatoclax
A 3-hour IV infusion for 3 consecutive days or a 24-hour infusion for 3 consecutive days every 2 weeks for up to 6 cycles.
Other Name: GX15-070MS

Detailed Description:
The Pilot Safety portion of the study will evaluate the safety of obatoclax administered by a 3 hour infusion for 3 days in a row. The Pilot Schedule portion of the study will randomize 16 patients in to one of two cohorts: 1) patients receiving obatoclax administered by a 3 hour infusion for 3 days in a row or 2) patients receiving obatoclax administered by a 24 hour infusion for 3 days in a row. The schedule with the best overall efficacy and safety in the Pilot Schedule portion of the study will then be utilized in the Phase II portion of the study.

Ages Eligible for Study:   70 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed AML
  • No prior chemotherapy for AML (with the exception that the patients enrolled in the Pilot Safety evaluation may have had 1 prior therapy)
  • Age ≥70 years
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2
  • Patients must have normal organ function as defined below:

    1. Total bilirubin < or = 2 mg/dL unless resulting from hemolysis,
    2. Aspartate transaminase (AST [SGOT])/alanine transaminase (ALT [SGPT]) < or = 2.5 x institutional ULN
    3. Creatinine within normal institutional limits, OR creatinine clearance > or = 50 mL/min/1.73 meters squared for patients with creatinine levels above institutional ULN

Exclusion Criteria:

  • Patients who have received or are receiving any other investigational or commercial agents or therapies administered with the intent to treat their malignancy (with the exception that the patients enrolled in the pilot safety evaluation may have had 1 prior therapy)
  • patients with history of allergic reactions attributed to components of the formulated product (PEG300 and polysorbate 20)
  • patients with history of seizure disorders or central nervous system leukemia
  • patients with uncontrolled, intercurrent illness including, but not limited to, symptomatic neurological illness; active, uncontrolled, systemic infection considered opportunistic, life-threatening, or clinically significant at the time of treatment; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; significant pulmonary disease or hypoxia; or psychiatric illness/social situations that would limit compliance with study requirements
  • Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00684918

United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Iowa
The University of Iowa
Iowa City, Iowa, United States, 52242
United States, Kansas
University of Kansas Medical Center Research Institute
Westwood, Kansas, United States, 66205
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, Michigan
St. Joseph Mercy Hospital
Ann Arbor, Michigan, United States, 48106
University of Michigan Health System
Ann Arbor, Michigan, United States, 48109
Michigan State University - Breslin Cancer Center
Lansing, Michigan, United States, 48910
United States, New York
St. Vincent's Comprehensive Cancer Center
New York, New York, United States, 10011
United States, Oregon
Legacy Emanuel Hospital & Health Center
Portland, Oregon, United States, 97210
United States, Pennsylvania
Penn State Hershey Cancer Institute-Clinical Trials Office
Hershey, Pennsylvania, United States, 17033
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Washington
Benaroya Research Institute at Virginia Mason
Seattle, Washington, United States, 98101
Canada, Ontario
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
Gemin X
Study Director: Jean Viallet, MD Gemin X Pharmaceuticals
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Gemin X Identifier: NCT00684918     History of Changes
Other Study ID Numbers: GEM016
Study First Received: May 23, 2008
Last Updated: August 16, 2013

Keywords provided by Teva Pharmaceutical Industries:
AML, obatoclax

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms processed this record on April 27, 2017